Back to results
US 2022/0089728 A1Published application
Antigen binding proteins
AssigneeGlaxoSmithKline Intellectual Property Development Limited
InventorsYan Y. DEGENHARDT, Jun Guan, Kenneth William Hance, Peter Joseph Morley
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions for treating CD96 mediated diseases, and related methods.
Claims21
-41. (canceled)
A CD96 binding protein comprising:
- CDRH1 of SEQ ID NO:
- 115;
- CDRH2 of SEQ ID NO:
- 145;
- CDRH3 of SEQ ID NO:
- 147;
- CDRL1 of SEQ ID NO:
- 97;
- CDRL2 of SEQ ID NO:
- 99;
- and
- CDRL3 of SEQ ID NO:
- 101.
10 more elements
Dependencies are inferred from the claim text.